Inovio provides an update on lassa fever and mers programs

Plymouth meeting, pa. , nov. 17, 2022 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and prevent infectious diseases, cancer, and diseases associated with hpv, today announced that it has agreed with its collaborator, the coalition for epidemic preparedness innovations (cepi), to discontinue development of product candidates targeting lassa fever (ino-4500) and middle east respiratory syndrome (mers) (ino-4700), following initial analyses of data from studies conducted by inovio and funded by cepi.
INO Ratings Summary
INO Quant Ranking